- Home
- JXG vs APVO Comparison
JXG vs APVO Comparison
Compare JXG & APVO Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.
- Machine Learning Prediction
- ML Decision
- JXG
- APVO
- Stock Information
- Founded
- JXG N/A
- APVO 2016
- Country
- JXG China
- APVO United States
- Employees
- JXG N/A
- APVO N/A
- Industry
- JXG
- APVO Biotechnology: Pharmaceutical Preparations
- Sector
- JXG
- APVO Health Care
- Exchange
- JXG Nasdaq
- APVO Nasdaq
- Market Cap
- JXG 5.2M
- APVO 5.4M
- IPO Year
- JXG N/A
- APVO N/A
- Fundamental
- Price
- JXG $2.39
- APVO $3.47
- Analyst Decision
- JXG
- APVO Strong Buy
- Analyst Count
- JXG 0
- APVO 1
- Target Price
- JXG N/A
- APVO $296.00
- AVG Volume (30 Days)
- JXG 34.7K
- APVO 44.0K
- Earning Date
- JXG 12-06-2024
- APVO 03-04-2025
- Dividend Yield
- JXG N/A
- APVO N/A
- EPS Growth
- JXG N/A
- APVO N/A
- EPS
- JXG 2.20
- APVO N/A
- Revenue
- JXG $38,490,872.00
- APVO N/A
- Revenue This Year
- JXG N/A
- APVO N/A
- Revenue Next Year
- JXG N/A
- APVO N/A
- P/E Ratio
- JXG $1.09
- APVO N/A
- Revenue Growth
- JXG N/A
- APVO N/A
- 52 Week Low
- JXG $0.75
- APVO $3.01
- 52 Week High
- JXG $4.92
- APVO $399.60
- Technical
- Relative Strength Index (RSI)
- JXG N/A
- APVO 33.42
- Support Level
- JXG N/A
- APVO $3.20
- Resistance Level
- JXG N/A
- APVO $3.65
- Average True Range (ATR)
- JXG 0.00
- APVO 0.34
- MACD
- JXG 0.00
- APVO 0.01
- Stochastic Oscillator
- JXG 0.00
- APVO 31.51
About JXG JX Luxventure Limited Common Stock
JX Luxventure Group Inc, formerly JX Luxventure Ltd is engaged in the tourism sector and supplying related products, including technology solutions, to business partners in China, both online and offline. The company operates in three segments Airline tickets and tourism services, Software Solutions for Tourism Cross-border operation, and Tourism Cross-border Merchandise. The majority of the group revenue is generated from Tourism products.
About APVO Aptevo Therapeutics Inc.
Aptevo Therapeutics Inc is a clinical-stage, research and development biotechnology company focused on developing novel immunotherapeutic candidates for the treatment of different forms of cancer. Its clinical candidate, APVO436, and preclinical candidates, ALG.APV-527 and APVO603, were developed using ADAPTIR modular protein technology platform. The versatile and robust ADAPTIR and ADAPTIR-FLEX platforms are designed to generate monospecific, bispecific, and multi-specific antibody candidates that are capable of enhancing the human immune system against cancer cells.